Export financials
Hill-Rom Holdings, Inc. (HRC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Hill-Rom Holdings, Inc. Financial Statements 2020-2011 | HRC
Annual Financial Statements Hill-Rom Holdings, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
6.07 B | 6.92 B | 5.58 B | 5.27 B | 3.64 B | 3.43 B | 2.54 B | 2.37 B | 1.73 B | 2.15 B |
Shares |
66.6 M | 66.6 M | 67.3 M | 65.8 M | 65.7 M | 65.2 M | 57.4 M | 58.5 M | 60.8 M | 61.7 M |
Net Income |
223 M | 152 M | 252 M | 134 M | 124 M | 47.7 M | 60.6 M | 105 M | 121 M | 133 M |
Revenue |
2.88 B | 2.91 B | 2.85 B | 2.74 B | 2.66 B | 1.99 B | 1.69 B | 1.72 B | 1.63 B | 1.59 B |
EBITDA |
518 M | 539 M | 564 M | 522 M | 479 M | 242 M | 266 M | 277 M | 303 M | 319 M |
Operating Expenses |
1.07 B | 1.08 B | 1.03 B | 1.01 B | 987 M | 756 M | 620 M | 620 M | 563 M | 566 M |
General and Administrative Expenses |
- | 941 M | 892 M | 876 M | 853 M | 664 M | 548 M | 550 M | 496 M | 502 M |
Annual performance
Select metrics to display
All numbers in USD currency
Main types of financial statements Hill-Rom Holdings, Inc. HRCFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Hill-Rom Holdings, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B | ||
|
Utah Medical Products
UTMD
|
$ 70.46 | -0.7 % | $ 228 M | ||
|
West Pharmaceutical Services
WST
|
$ 389.88 | -1.72 % | $ 28.2 B | ||
|
Baxter International
BAX
|
$ 25.39 | -0.02 % | $ 13 B | ||
|
Glaukos Corporation
GKOS
|
$ 236.75 | -0.63 % | $ 13.5 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Milestone Scientific
MLSS
|
$ 0.24 | -0.83 % | $ 19.7 M | ||
|
Alcon
ALC
|
$ 74.29 | -0.32 % | $ 36.6 B | ||
|
AtriCure
ATRC
|
$ 55.37 | 2.33 % | $ 2.64 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 212.18 | -0.26 % | $ 61 B | ||
|
AngioDynamics
ANGO
|
$ 10.8 | 0.37 % | $ 448 M | ||
|
The Cooper Companies
COO
|
$ 58.8 | -2.54 % | $ 11.7 B | ||
|
Intuitive Surgical
ISRG
|
$ 400.35 | -1.69 % | $ 143 B | ||
|
Repro Med Systems
KRMD
|
$ 3.19 | -7.41 % | $ 147 M | ||
|
InfuSystem Holdings
INFU
|
$ 14.39 | 2.35 % | $ 297 M | ||
|
electroCore
ECOR
|
$ 4.5 | -7.22 % | $ 38.2 M | ||
|
OraSure Technologies
OSUR
|
$ 3.48 | -3.6 % | $ 256 M | ||
|
iRhythm Technologies
IRTC
|
$ 94.92 | 0.72 % | $ 3.04 B | ||
|
ResMed
RMD
|
$ 235.13 | -0.78 % | $ 34.2 B | ||
|
Harvard Bioscience
HBIO
|
$ 8.62 | -0.69 % | $ 383 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Retractable Technologies
RVP
|
$ 0.56 | -6.53 % | $ 16.8 M | ||
|
Microbot Medical
MBOT
|
$ 0.68 | -8.79 % | $ 31.1 M | ||
|
Haemonetics Corporation
HAE
|
$ 119.94 | -0.3 % | $ 5.66 B | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
STERIS plc
STE
|
$ 255.68 | 0.31 % | $ 25.1 B | ||
|
ICU Medical
ICUI
|
$ 172.0 | -2.14 % | $ 4.24 B | ||
|
Merit Medical Systems
MMSI
|
$ 84.35 | -0.07 % | $ 4.99 B | ||
|
Nephros
NEPH
|
$ 2.72 | -4.26 % | $ 28.9 M | ||
|
Pro-Dex
PDEX
|
$ 62.2 | -2.03 % | $ 201 B | ||
|
Envista Holdings Corporation
NVST
|
$ 22.85 | -1.63 % | $ 3.84 B | ||
|
LeMaitre Vascular
LMAT
|
$ 73.73 | -1.52 % | $ 1.67 B | ||
|
Pulse Biosciences
PLSE
|
$ 45.42 | 2.27 % | $ 3.06 B | ||
|
Repligen Corporation
RGEN
|
$ 163.68 | -3.88 % | $ 9.2 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
STAAR Surgical Company
STAA
|
$ 24.2 | -3.32 % | $ 1.2 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Teleflex Incorporated
TFX
|
$ 161.56 | -1.16 % | $ 7.21 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 8.27 | -2.65 % | $ 1.65 B | ||
|
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Masimo Corporation
MASI
|
- | - | $ 9.59 B | ||
|
Stereotaxis
STXS
|
$ 0.95 | -6.44 % | $ 86.4 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M |